TABLE 4.

Risk of neuropsychiatric events (NPEs) in relation to leukotriene receptor antagonist (LTRA) use in patients with asthma or allergic rhinitis according to type of NPE: psychotic, mood, anxiety and sleep-related disorders

	Psychotic disorder				Mood disorder				Anxiety disorder				Sleep-related disorder
	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value
Unexposed	466	968.7	1		5298	11 120.18	1		13 108	29 123.82	1		8973	19 983.28	1
Exposed	18	42.33	1.19 (0.69–1.91)	0.506	172	375.86	1.16 (0.98–1.36)	0.072	307	786.61	1.01 (0.89–1.13)	0.911	219	603.5	0.92 (0.80–1.06)	0.259
Time since initiation of LTRA (days)
1–3	2	9.09	0.56 (0.14–2.25)	0.413	30	96.68	0.75 (0.51–1.06)	0.121	53	248.15	0.54 (0.41–0.70)	<0.001	62	179.41	0.87 (0.67–1.11)	0.289
4–7	2	5.74	0.91 (0.23–3.70)	0.901	43	53.57	1.96 (1.42–2.62)	<0.001	107	123.67	2.20 (1.81–2.66)	<0.001	62	95.91	1.64 (1.26–2.09)	<0.001
8–14	6	6.44	2.56 (1.12–5.84)	0.025	39	56.03	2.16 (1.6–2.84)	<0.001	68	115.42	1.51 (1.17–1.90)	<0.001	44	94.48	1.18 (0.86–1.57)	0.281
15–30	2	7.98	0.69 (0.17–2.81)	0.607	26	67.12	0.97 (0.64–1.41)	0.882	40	127.52	0.80 (0.57–1.08)	0.159	20	103.15	0.49 (0.3–0.74)	0.001
31–90	5	8.54	1.78 (0.70–4.48)	0.224	18	67.95	0.68 (0.41–1.05)	0.106	25	114.21	0.56 (0.37–0.82)	0.004	21	93.66	0.56 (0.35–0.84)	0.009
>90	1	4.54	0.78 (0.10–6.03)	0.808	6	34.51	0.47 (0.18–1.00)	0.079	14	57.63	0.67 (0.37–1.13)	0.164	10	36.89	0.64 (0.31–1.17)	0.181

IRR: incidence rate ratio.